Menu

Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg™ (Pegfilgrastim-unne)

December 1, 2025

Mumbai, Naples, December 1, 2025: Global pharma major Lupin Limited (Lupin), today announced that the United States Food and Drug Administration (U.S. FDA) has approved Armlupeg™ (pegfilgrastim-unne) 6 mg/0.6 mL injection for subcutaneous use in a single-dose prefilled syringe, as biosimilar to Neulasta® (pegfilgrastim) 6 mg/0.6 mL injection. The product will be manufactured at Lupin’s Biotech facility in Pune, which was inspected by the U.S. FDA prior to approval.

Armlupeg™ is indicated for:

  • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
  • Increase survival in patients acutely exposed to myelosuppressive doses of radiation.

“We are proud to achieve the FDA approval for our first biosimilar, Pegfilgrastim. This step marks a pivotal step in Lupin’s ongoing commitment to providing more affordable, accessible medicines to U.S. patients. We look forward to introducing a robust portfolio of biosimilars over the next few years, which will help improve the quality of care for the communities and patients we serve,” said Vinita Gupta, CEO, Lupin.

Nilesh Gupta, MD, Lupin, said, “Our integrated biologic capabilities encompass the entire spectrum, from initial cell line development to upstream/downstream process optimization and clinical development. This, coupled with our state-of-the-art biologic facility that has now been approved by every major regulatory body, ensures that we deliver biosimilars that meet the highest global quality standards while achieving the scale necessary for global affordability.”

“We are pleased to have obtained approval for Pegfilgrastim. This milestone demonstrates Lupin’s unwavering commitment to reducing barriers to treatment and empowering patients with greater choice and confidence in their healthcare journey,” said Dr. Cyrus Karkaria, President, Biotechnology, Lupin.

Pegfilgrastim 6 mg/0.6 mL injection for subcutaneous use in a single-dose prefilled syringe had estimated annual sales of USD 1,295 million in the U.S. for the 12 months ending September 2025 (IQVIA MAT).

About Lupin 
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn 
https://www.linkedin.com/company/lupin

For further information or queries, please contact

Rajalakshmi Azariah 
Vice President & Global Head – Corporate Communications, Lupin  
rajalakshmiazariah@lupin.com   

*Safe Harbor Statement
Neulasta® is a registered trademark of Amgen Inc.

Latest Press Releases

Smart Guide
Consent to Collection Cookie

This website uses cookies to enhance your overall web browsing experience, provide you with ads tailored to your interests, and allow us to measure our audience and collect other analytical data about the use of our website.

By clicking "Accept All" you consent to the collection of your personal information (which may include your Consumer Health Data) through 1st and 3rd party cookies (or similar). To edit your cookie preferences, use the options below.

For more information, please visit our Privacy Statement.

Depending on where you live, you may also be able to exercise your right to opt out or withdraw your consent.Do Not Sell/Share My Personal Information.

Global Privacy Control Detected

We have detected your Global Privacy Control (GPC) signal. In accordance with applicable privacy laws, we have automatically honored your preference and disabled all non-essential cookies and tracking.

Only necessary cookies required for the website to function are enabled.

Opt-Out Request Honored

We have respected your privacy preference. Your opt-out request through cookie settings or Global Privacy Control signal has been honored.